Correction to: Nature Reviews Clinical Oncology https://doi.org/10.1038/s41571-021-00527-8, published online 25 May 2021.
In the originally published article, the 95% confidence interval for patients with IDH-mutant disease with and without concurrent temozolomide was incorrect: 0.35−0.67. Instead, this confidence interval is 0.58–1.10. These values have been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, D. Author Correction: Anaplastic glioma: benefit of temozolomide clarified. Nat Rev Clin Oncol 18, 468 (2021). https://doi.org/10.1038/s41571-021-00531-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00531-y
